A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors
Authors
Keywords
sodium glucose co-transporter 2 inhibitors, type 2 diabetes, chronic kidney disease, nephropathy
Journal
Cell Metabolism
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-03-10
DOI
10.1016/j.cmet.2021.02.016
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights from the CREDENCE Trial
- (2021) Nan Ye et al. CIRCULATION
- Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects
- (2020) Matthew Griffin et al. CIRCULATION
- Empagliflozin modulates renal sympathetic and heart rate baroreflexes in a rabbit model of diabetes
- (2020) Cindy Gueguen et al. DIABETOLOGIA
- Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function
- (2020) Erik J.M. van Bommel et al. KIDNEY INTERNATIONAL
- Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes
- (2020) JingWei Li et al. KIDNEY INTERNATIONAL
- SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition
- (2020) Issei Tomita et al. Cell Metabolism
- Proximal Tubule mTORC1 Is a Central Player in the Pathophysiology of Diabetic Nephropathy and Its Correction by SGLT2 Inhibitors
- (2020) Aviram Kogot-Levin et al. Cell Reports
- Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination with Loop Diuretics in Patients with Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial
- (2020) Natalie A. Mordi et al. CIRCULATION
- Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Results of DAPA-HF
- (2020) Pardeep S. Jhund et al. CIRCULATION
- Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study
- (2020) Austin G Stack et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Role of ketogenic starvation sensors in mediating the renal protective effects of SGLT2 inhibitors in type 2 diabetes
- (2020) Milton Packer JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin ameliorates renal oxidative stress and inflammation by stimulating AMPK–Akt–eNOS pathway in the isoprenaline-induced oxidative stress model
- (2020) Raquibul Hasan et al. Scientific Reports
- Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial
- (2020) Rosalie A. Scholtes et al. DIABETES CARE
- Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
- (2020) David C Wheeler et al. Lancet Diabetes & Endocrinology
- 24-Hour Blood Pressure-Lowering Effect of an SGLT-2 Inhibitor in Patients with Diabetes and Uncontrolled Nocturnal Hypertension: Results from the Randomized, Placebo-Controlled SACRA Study
- (2019) Kazuomi Kario et al. CIRCULATION
- Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
- (2019) Hiddo J. L. Heerspink et al. DIABETOLOGIA
- Empagliflozin restores the integrity of the endothelial glycocalyx in vitro
- (2019) Scott Cooper et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging
- (2019) Kengo Kidokoro et al. CIRCULATION
- Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes
- (2019) Skander Mulder et al. DIABETES OBESITY & METABOLISM
- Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes
- (2019) Claire C. J. Dekkers et al. DIABETES OBESITY & METABOLISM
- SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
- (2019) Brendon L Neuen et al. Lancet Diabetes & Endocrinology
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Effect of Empagliflozin on Erythropoietin Levels, Iron Stores and Red Blood Cell Morphology in Patients with Type 2 Diabetes and Coronary Artery Disease
- (2019) C. David Mazer et al. CIRCULATION
- Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes
- (2019) JingWei Li et al. JACC-Heart Failure
- The Role of Inflammasome-Dependent and Inflammasome-Independent NLRP3 in the Kidney
- (2019) Yang Gyun Kim et al. Cells
- Reinterpreting Cardiorenal Protection of Renal Sodium–Glucose Cotransporter 2 Inhibitors via Cellular Life History Programming
- (2019) Angelo Avogaro et al. DIABETES CARE
- Metformin alleviates oxidative stress and enhances autophagy in diabetic kidney disease via AMPK/SIRT1-FoxO1 pathway
- (2019) Huiwen Ren et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers
- (2018) Claire C. J. Dekkers et al. DIABETES OBESITY & METABOLISM
- Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms
- (2018) Sarah J. Mancini et al. Scientific Reports
- Inhibition of insulin resistance by PGE1 via autophagy-dependent FGF21 pathway in diabetic nephropathy
- (2018) Wei Wei et al. Scientific Reports
- Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control
- (2018) Silvio E. Inzucchi et al. CIRCULATION
- Sodium-glucose cotransporter 2 inhibitors regulate ketone body metabolism via inter-organ crosstalk
- (2018) Jin Hee Kim et al. DIABETES OBESITY & METABOLISM
- Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial
- (2018) Christoph Wanner et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2
- (2017) Vance B. Matthews et al. JOURNAL OF HYPERTENSION
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- β-Hydroxybutyrate Deactivates Neutrophil NLRP3 Inflammasome to Relieve Gout Flares
- (2017) Emily L. Goldberg et al. Cell Reports
- Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials
- (2017) Sophia Zoungas et al. Lancet Diabetes & Endocrinology
- Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus
- (2016) Hiroyuki Tanaka et al. ADVANCES IN THERAPY
- Empagliflozin’s Fuel Hypothesis: Not so Soon
- (2016) Gary D. Lopaschuk et al. Cell Metabolism
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
- (2016) Sunder Mudaliar et al. DIABETES CARE
- Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
- (2015) Hiroaki Iijima et al. ADVANCES IN THERAPY
- Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
- (2015) R. Chilton et al. DIABETES OBESITY & METABOLISM
- The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome–mediated inflammatory disease
- (2015) Yun-Hee Youm et al. NATURE MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metabolic syndrome: a sympathetic disease?
- (2015) Markus Schlaich et al. Lancet Diabetes & Endocrinology
- The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
- (2014) David ZI Cherney et al. Cardiovascular Diabetology
- Glucosamine-Induced Sp1 O-GlcNAcylation Ameliorates Hypoxia-Induced SGLT Dysfunction in Primary Cultured Renal Proximal Tubule Cells
- (2014) Han Na Suh et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis
- (2014) H. J. Lambers Heerspink et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Caloric restriction ameliorates kidney ischaemia/reperfusion injury through PGC-1α-eNOS pathway and enhanced autophagy
- (2013) J. Lempiäinen et al. Acta Physiologica
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Effect of Plasma Uric Acid on Antioxidant Capacity, Oxidative Stress, and Insulin Sensitivity in Obese Subjects
- (2013) E. Fabbrini et al. DIABETES
- Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes
- (2013) R. A. DeFronzo et al. DIABETES CARE
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- Glomerular hyperfiltration: definitions, mechanisms and clinical implications
- (2012) Imed Helal et al. Nature Reviews Nephrology
- Serum Uric Acid Levels and Incident Chronic Kidney Disease in Patients With Type 2 Diabetes and Preserved Kidney Function
- (2011) G. Zoppini et al. DIABETES CARE
- Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney
- (2010) Shinji Kume et al. JOURNAL OF CLINICAL INVESTIGATION
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started